EA201001508A1 - Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич - Google Patents

Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич

Info

Publication number
EA201001508A1
EA201001508A1 EA201001508A EA201001508A EA201001508A1 EA 201001508 A1 EA201001508 A1 EA 201001508A1 EA 201001508 A EA201001508 A EA 201001508A EA 201001508 A EA201001508 A EA 201001508A EA 201001508 A1 EA201001508 A1 EA 201001508A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bridges
hiv integrase
heterocyclic compounds
integrase inhibitors
hiv
Prior art date
Application number
EA201001508A
Other languages
English (en)
Inventor
Франсис Больё
Карл Уэллет
Б. Нарасимхулу Наиду
Манодж Патель
Ясутсугу Уэда
Тимоти П. Конноли
Джонатан Р. Вайс
Майкл А. Уокер
Николас А. Минвелл
Кевин М. Пиз
Маргарет Е. Соренсон
Чэнь Ли
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201001508A1 publication Critical patent/EA201001508A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems

Abstract

Данное изобретение в общем относится к новьм соединениям формулы I, включая их соли, которые ингибируют интегразу ВИЧ и предотвращают интеграцию вирусов в человеческую ДНК. Этот механизм делает соединения полезными для лечения ВИЧ-инфекции и СПИДа. Данное изобретение охватывает также фармацевтические композиции и способы лечения больных, инфицированных ВИЧ.
EA201001508A 2008-03-19 2009-03-19 Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич EA201001508A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3772908P 2008-03-19 2008-03-19
US12/406,268 US8129398B2 (en) 2008-03-19 2009-03-18 HIV integrase inhibitors
PCT/US2009/037596 WO2009117540A1 (en) 2008-03-19 2009-03-19 Bridged heterocycles as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
EA201001508A1 true EA201001508A1 (ru) 2011-04-29

Family

ID=40863725

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001508A EA201001508A1 (ru) 2008-03-19 2009-03-19 Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич

Country Status (15)

Country Link
US (1) US8129398B2 (ru)
EP (1) EP2280981B8 (ru)
JP (1) JP2011515412A (ru)
KR (1) KR20100137522A (ru)
CN (1) CN102036996A (ru)
AU (1) AU2009225577A1 (ru)
BR (1) BRPI0910307A2 (ru)
CA (1) CA2718950A1 (ru)
CO (1) CO6331439A2 (ru)
EA (1) EA201001508A1 (ru)
IL (1) IL208068A0 (ru)
MX (1) MX2010009995A (ru)
NZ (1) NZ588031A (ru)
WO (1) WO2009117540A1 (ru)
ZA (1) ZA201006589B (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516333A (ja) * 2009-01-28 2012-07-19 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖインテグラーゼ阻害剤としての架橋化合物
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8383639B2 (en) * 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
JP6266978B2 (ja) 2010-08-10 2018-01-24 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
US8835411B2 (en) 2010-12-10 2014-09-16 Bristol-Myers Squibb Company HIV integrase inhibitors
US8846659B2 (en) 2010-12-10 2014-09-30 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2012077221A1 (ja) * 2010-12-10 2012-06-14 アグロカネショウ株式会社 ３-アミノオキサリルアミノベンズアミド誘導体及びこれを有効成分とする殺虫、殺ダニ剤
CN102675305B (zh) * 2011-03-08 2014-11-12 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014008636A1 (en) * 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
US8906929B2 (en) * 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CA3012242C (en) 2012-12-21 2021-11-02 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014107536A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2737434C2 (ru) 2013-03-13 2020-11-30 Форма Терапьютикс, Инк. Новые соединения и композиции для ингибирования fasn
JP6268656B2 (ja) * 2013-03-14 2018-01-31 ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶ Ｈｅａｌｔｈｃａｒｅ ＵＫ （Ｎｏ．５） Ｌｉｍｉｔｅｄ ヒト免疫不全ウイルス複製の阻害剤
NO2865735T3 (ru) 2013-07-12 2018-07-21
JP6411491B2 (ja) 2013-07-12 2018-10-24 ギリアード サイエンシス インコーポレーテッド 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用
CN103601613B (zh) * 2013-11-19 2015-07-08 浙江林江化工股份有限公司 一种3,4,5-三氟溴苯的制备方法
US9815796B2 (en) 2013-12-23 2017-11-14 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as PDE2 inhibitors
LT3140310T (lt) 2014-05-05 2019-11-25 Rempex Pharmaceuticals Inc Boronato druskų sintezė ir jų panaudojimas
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112016026291A2 (pt) 2014-05-19 2017-08-15 Rempex Pharmaceuticals Inc Derivados do ácido borônico e usos terapêuticos dos mesmos
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (ru) 2014-06-20 2018-06-23
KR20170024087A (ko) 2014-07-01 2017-03-06 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016154081A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
AU2016244035B2 (en) 2015-04-02 2018-11-01 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017059120A1 (en) * 2015-09-30 2017-04-06 Gilead Sciences, Inc. Compounds and combinations for the treatment of hiv
CA3026582A1 (en) 2016-06-30 2018-01-04 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2020003495A (es) 2017-10-11 2020-09-18 Qpex Biopharma Inc Derivados de acido boronico y sintesis de los mismos.
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
WO2020197991A1 (en) * 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
CA3166480A1 (en) 2020-02-24 2021-09-02 Lan Jiang Tetracyclic compounds for treating hiv infection
PE20231297A1 (es) 2021-01-19 2023-08-22 Gilead Sciences Inc Compuestos de piridotriazina sustituidos y usos de estos

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058757A1 (en) * 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) * 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
EP1866313A1 (en) 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors
US7741315B2 (en) 2005-05-10 2010-06-22 Merck Sharp & Dohme Corp. HIV integrase inhibitors
US7494984B2 (en) * 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
WO2007059125A2 (en) 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Hiv integrase inhibitors
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
US7897593B2 (en) 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
US7763630B2 (en) 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
JP2012516333A (ja) * 2009-01-28 2012-07-19 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖインテグラーゼ阻害剤としての架橋化合物

Also Published As

Publication number Publication date
CO6331439A2 (es) 2011-10-20
US20090253677A1 (en) 2009-10-08
KR20100137522A (ko) 2010-12-30
MX2010009995A (es) 2010-09-30
AU2009225577A1 (en) 2009-09-24
ZA201006589B (en) 2012-02-29
NZ588031A (en) 2011-12-22
WO2009117540A1 (en) 2009-09-24
EP2280981B8 (en) 2014-09-17
EP2280981A1 (en) 2011-02-09
CN102036996A (zh) 2011-04-27
US8129398B2 (en) 2012-03-06
BRPI0910307A2 (pt) 2019-09-24
EP2280981B1 (en) 2014-04-23
IL208068A0 (en) 2010-12-30
CA2718950A1 (en) 2009-09-24
JP2011515412A (ja) 2011-05-19

Similar Documents

Publication Publication Date Title
EA201001508A1 (ru) Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201291300A1 (ru) Производные нафт-2-илуксусной кислоты для лечения спида
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA200971026A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
MX2010005292A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
EA201500266A1 (ru) Ингибиторы репликации вирусов гриппа
EA201100613A1 (ru) Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
EA201291301A1 (ru) Производные 2-хинолинилуксусной кислоты в качестве противовирусных соединений против вич
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201391395A1 (ru) Терапевтические соединения
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201001273A1 (ru) Ингибиторы вируса гепатита с
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2